GE HealthCare

Who we are

GE HealthCare (Nasdaq: GEHC) is a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across the care pathway.

Our key metrics

- 1B+ patients served annually
- 100+ years legacy
- 51,000+ colleagues
- 4M+ installed base equipment
- $19.6B revenue
- $1B+ annual R&D and product investment spend
- 58 AI-enabled medical device authorizations, topping U.S. FDA list [a]

Our four business units

Imaging: Medical imaging solutions including CT, MR, molecular imaging, X-ray, women's health, image-guided therapies, enterprise imaging software, service capabilities, and digital solutions.
- **Milestone:** FDA clearance for state-of-the-art deep learning-based technology that enables MR cardiac imaging within a single heartbeat and can help reduce scan time by up to 83%.

Ultrasound: Consoles and probes, handheld devices, intraoperative imaging systems, visualization software, service capabilities, and digital solutions.
- **Milestone:** Pioneered the first handheld ultrasound in 2010. In 2021, we made it wireless and pocket-sized with crystal clear image quality for whole-body scanning and added intuitive software - all in the palm of clinicians' hands.

Patient Care Solutions: Monitoring, anesthesia and respiratory care, maternal infant care, and diagnostic cardiology solutions, as well as consumables, service capabilities, and digital solutions.
- **Milestone:** FDA clearance for a first-of-its-kind, wireless monitoring solution aiding early detection of patient deterioration.

Pharmaceutical Diagnostics: Contrast media and radiopharmaceuticals agents that enhance diagnostic images.
- **Milestone:** Introduced the first and only FDA-approved PET agent for color imaging of amyloid plaque now being used to aid in the diagnosis of Alzheimer's disease in patients with cognitive decline.

Creating a world where healthcare has no limits

- **We are an $19.6 billion business** with over 51,000 colleagues working to create a world where healthcare has no limits
- **We execute on our precision care strategy** at the forefront of care delivery across the patient journey
- **We play a central role in healthcare digitization** with 200+ software apps driving breakthroughs in clinical insights
- **We are an industry-defining innovator** with 9,700 engineers and scientists focused on R&D
- **We are a leader in an attractive $84B global healthcare market,** growing 4-6% per year
- **We are led by an experienced leadership team** with the right strategic vision:
  - Peter J. Arduini- President and Chief Executive Officer
  - James (Jay) Saccaro- Vice President and Chief Financial Officer

Our care pathway approach

Our global teams collaborate to deliver products, services and solutions that touch nearly every part of the patient journey across key disease-specific states like cardiology, neurology and oncology. We are innovating to help clinicians improve patient outcomes and reduce the time from diagnosis to treatment.

Innovation

We are a proven innovator with a history of delivering industry firsts to advance the future of healthcare: first full-body CT, commercialization of MR, handheld ultrasound, first and only iso-osmolar contrast medium, first hospital command center, and topping the FDA's list with the most AI-enabled device authorizations of any medtech company, with 58[a]. We are developing new capabilities for the future, leveraging AI and machine learning to connect healthcare workflows across operations, data silos, and analytics.

Trusted partner

Our portfolio of solutions addresses the biggest challenges facing the healthcare industry today, including helping clinicians provide better outcomes, improve operational efficiencies and enhance productivity. These qualities foster trust, loyalty, and partnership with our global customer base in over 160 countries.

Notes: Figures as of 2023 unless otherwise noted
(a – Source: As of October 2023: https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices

*All data is accurate as of December 2023